Wednesday, April 13, 2016 4:47:05 PM
Mizuho Securities. 4/13/2016
http://kabutan.jp/
U.S. Athersys shows efficacy against acute cerebral infarction in the Phase 2 study. Conservative stock spread originates from a new field of cell medicine.
Current point, there is no choice of other treatments for this serious life threatening disease. In that, this will change the way of thinking with more and more use, that can be expected.
Domestic health care costs are rising, tailwind in early treatment promotion of this disease is necessary to long-term care, such as cerebral infarction.
"BUY" rating and raised the target price to 1660 yen ($15.19 usd) to 1960 yen ($17.94).
"MK" Kabusagu News
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM